Work

Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.103

Authors: Ajjai Shivaram Alva, Jinju Li, Jonathan Chou, Melissa Andrea Reimers, Rana R. McKay, Jingsong Zhang, Stephanie Daignault-Newton, Phillip Lee Palmbos, Zachery R Reichert, Marcin Cieslik, Arul Chinnaiyan, Wassim Abida

Institutions: U-M Rogel Cancer Center, University of Michigan, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Washington University in St. Louis, University of California San Diego, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4213286264

Cites:

Cited by: 6

Related to: 10